What is Fayuvi, the first gene therapy for Sanfilippo syndrome Type A?

We have folded our coverage of this story into one complete guide: Is there really a first FDA-approved treatment for Sanfilippo syndrome?

The short version: Fayuvi is the first gene therapy approved for pediatric patients with Sanfilippo syndrome type A, a rare inherited disorder that prevents the body from properly breaking down cellular waste. For the full picture — how the therapy works, what FDA approval actually means, what families usually do next, and what to watch from here — read the complete guide.

Why a first gene therapy approval matters

Sanfilippo syndrome Type A is rare, so families have historically had very few options and little public attention. A first approved gene therapy matters because regulators have reviewed evidence that a treatment targeting the underlying cause can be made and given to patients. Approval is a starting point, not an ending — follow-up evidence, access, and long-term monitoring still shape what it means in practice.

What to do, step by step

1. Read the complete guide linked above for how the therapy works plainly.
2. Separate what approval confirms from questions longer follow-up must answer.
3. Use the approval announcement and regulator information as primary sources.
4. Families with questions should raise them with their own specialist team.
5. Watch for published follow-up results rather than headlines or social posts.